Crocs, Inc. (NASDAQ:CROX) CEO Andrew Rees sold 5,100 shares of Crocs stock in a transaction on Thursday, January 7th. The shares were sold at an average price of $70.12, for a total value of $357,612.00. Following the transaction, the chief executive officer now directly owns 849,848 shares of the company’s stock, valued at $59,591,341.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Andrew Rees also recently made the following trade(s):
- On Monday, January 11th, Andrew Rees sold 34,900 shares of Crocs stock. The stock was sold at an average price of $72.10, for a total transaction of $2,516,290.00.
- On Monday, November 30th, Andrew Rees sold 8,600 shares of Crocs stock. The shares were sold at an average price of $60.04, for a total transaction of $516,344.00.
- On Thursday, October 29th, Andrew Rees sold 31,552 shares of Crocs stock. The shares were sold at an average price of $54.00, for a total transaction of $1,703,808.00.
Crocs stock opened at $76.36 on Thursday. The company has a market cap of $5.15 billion, a PE ratio of 34.87, a PEG ratio of 1.51 and a beta of 1.77. The company has a current ratio of 1.70, a quick ratio of 1.07 and a debt-to-equity ratio of 0.59. Crocs, Inc. has a 1 year low of $8.40 and a 1 year high of $78.68. The company’s 50-day moving average is $64.03 and its two-hundred day moving average is $48.92.
Several hedge funds have recently bought and sold shares of CROX. Glenmede Trust Co. NA boosted its position in shares of Crocs by 50.9% in the 2nd quarter. Glenmede Trust Co. NA now owns 996 shares of the textile maker’s stock worth $36,000 after purchasing an additional 336 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of Crocs during the 3rd quarter worth about $53,000. Cerebellum GP LLC bought a new stake in shares of Crocs in the 3rd quarter valued at about $64,000. Neo Ivy Capital Management bought a new stake in shares of Crocs in the 3rd quarter valued at about $68,000. Finally, FMR LLC raised its position in shares of Crocs by 54.2% in the 1st quarter. FMR LLC now owns 2,846 shares of the textile maker’s stock valued at $73,000 after acquiring an additional 1,000 shares during the period. 95.34% of the stock is currently owned by institutional investors.
CROX has been the subject of a number of research analyst reports. Loop Capital lifted their target price on shares of Crocs from $60.00 to $75.00 in a research note on Wednesday, December 9th. BidaskClub downgraded Crocs from a “strong-buy” rating to a “buy” rating in a research report on Monday, December 28th. Monness Crespi & Hardt boosted their price objective on Crocs from $60.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird raised their target price on Crocs from $50.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. Finally, Pivotal Research upped their price target on shares of Crocs from $68.00 to $87.00 and gave the stock a “buy” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $72.50.
Crocs, Inc, together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children worldwide. It offers various footwear products, including clogs, sandals, flips and slides, shoes, and boots under the Crocs brand name.
Read More: Market Capitalization
Receive News & Ratings for Crocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crocs and related companies with MarketBeat.com's FREE daily email newsletter.